Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Caribou Biosciences (CRBU)
NASDAQ:CRBU
Caribou Biosciences (CRBU) Stock Price & Analysis
607 Followers
CRBU Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.50 - $8.33
Previous Close$2.3
Volume893.15K
Average Volume (3M)2.60M
Market Cap
$203.21M
Enterprise Value-$59.55M
Total Cash (Recent Filing)$293.99M
Total Debt (Recent Filing)$27.16M
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Aug 06, 2024EPS Estimate
-$0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.45
Shares Outstanding90,317,771
10 Day Avg. Volume3,572,168
30 Day Avg. Volume2,601,803
Standard Deviation0.28
R-Squared0.20
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)0.42
Price to Sales (P/S)4.51
Price to Cash Flow (P/CF)-1.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-1.78
Enterprise Value/Gross Profit-1.73
Enterprise Value/Ebitda0.53
Forecast
1Y Price Target
$14.67Price Target Upside552.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Caribou Biosciences News
PremiumCompany Announcements
Caribou Biosciences Updates on CAR-T Therapy Trial and ASCO Presentation
Bulls Say, Bears Say
Bulls Say
Clinical TrialsSecond-line LBCL dose expansion results from the ANTLER trial showed CB-010 achieved a 94% objective response rate and 69% complete response rate.
Financial PerformanceExtending cash runway by approximately 6 months into the second half of 2026.
Strategic FocusCaribou announced that it is discontinuing preclinical research activities associated with its allogeneic CAR-NK platform and will be reducing its workforce by approximately 12%.
Bears Say
Competitive LandscapeThe broader competitive landscape in LBCL has led to a lower probability of approval for CB-010 and CB-011.
Regulatory And Clinical RisksRisks include negative clinical results with the company's lead assets, delays in advancing these candidates into registrational programs, and inability to obtain regulatory approvals in a timely manner or at all.
Strategic ChangesAnnouncing the discontinuation of its preclinical allogeneic CAR-NK platform and workforce reduction of around 12%.
---
Ownership Overview
8.74% Insiders
10.06% Mutual Funds
12.78% Other Institutional Investors
68.42% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRBU FAQ
What was Caribou Biosciences’s price range in the past 12 months?
Caribou Biosciences lowest stock price was $1.50 and its highest was $8.33 in the past 12 months.
What is Caribou Biosciences’s market cap?
Currently, no data Available
When is Caribou Biosciences’s upcoming earnings report date?
Caribou Biosciences’s upcoming earnings report date is Aug 06, 2024 which is in 15 days.
How were Caribou Biosciences’s earnings last quarter?
Caribou Biosciences released its earnings results on May 07, 2024. The company reported -$0.46 earnings per share for the quarter, missing the consensus estimate of -$0.411 by -$0.049.
Is Caribou Biosciences overvalued?
According to Wall Street analysts Caribou Biosciences’s price is currently Undervalued.
Does Caribou Biosciences pay dividends?
Caribou Biosciences does not currently pay dividends.
What is Caribou Biosciences’s EPS estimate?
Caribou Biosciences’s EPS estimate is -$0.46.
How many shares outstanding does Caribou Biosciences have?
Caribou Biosciences has 90,317,770 shares outstanding.
What happened to Caribou Biosciences’s price movement after its last earnings report?
Caribou Biosciences reported an EPS of -$0.46 in its last earnings report, missing expectations of -$0.411. Following the earnings report the stock price went down -6.166%.
Which hedge fund is a major shareholder of Caribou Biosciences?
Among the largest hedge funds holding Caribou Biosciences’s share is Maverick Capital ltd. It holds Caribou Biosciences’s shares valued at 3M.
---
Caribou Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.67 (552.00% Upside)
$14.67 (552.00% Upside)
Blogger Sentiment
Bullish
CRBU Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 897.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days <0.1%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.79%
12-Months-Change
Fundamentals
Return on Equity
-37.09%
Trailing 12-Months
Asset Growth
17.08%
Trailing 12-Months
Company Description
Caribou Biosciences
Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies.
---
CRBU Stock 12 Month Forecast
Average Price Target
$14.67
▲(552.00% Upside)
Technical Analysis
Editas Medicine
―
Crispr Therapeutics AG
―
Intellia Therapeutics
―
Beam Therapeutics
―
Best Analysts Covering CRBU
1 Year
1 Year Success Rate
3/22 ratings generated profit
1 Year Average Return
-34.24%
reiterated a buy rating 7 days ago
Copying Mani Foroohar's trades and holding each position for 1 Year would result in 13.64% of your transactions generating a profit, with an average return of -34.24% per trade.
---